Results
Overall, 118 patients with complete data were recruited into the final analysis. Irrespective of disease stages, both HQG and PR groups showed improving trends across 6-minute walk test and quality of life scores, while the medical treatment group demonstrated either no improvements or some deteriorations. When comparing HQG with PR, HQG appeared to have better effects on decreasing the frequency of exacerbation for patients with GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage I and maintaining a stable tumor necrosis factor-alpha level for patients of GOLD stage II.